Nursing care
Non-statin lipid drugs: ezetimibe, PCSK9 inhibitors, fibrates, niacin and resins
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Non-statin lipid drugs each have a distinct nursing angle. Ezetimibe blocks cholesterol absorption, PCSK9 inhibitors are injected to raise LDL receptor activity, fibrates lower triglycerides but add muscle risk with statins, niacin causes flushing, and bile acid sequestrants bind other drugs and cause constipation. Dose timing, muscle symptoms and liver tests drive monitoring.
Ezetimibe and PCSK9 inhibitors lower LDL by different routes
Ezetimibe blocks an intestinal transporter so less dietary and biliary cholesterol is absorbed, which prompts the liver to clear more LDL from the blood. It is taken once daily with or without food and is often added to a statin. Liver tests are checked, and new muscle pain is reported, particularly when it is combined with a statin.
PCSK9 inhibitors such as evolocumab and alirocumab are monoclonal antibodies injected subcutaneously at intervals of weeks; inclisiran is a newer agent given less often by a clinician. By stopping LDL receptor breakdown, they lower LDL substantially. Teach injection technique and site rotation, and ask about injection site reactions, nasopharyngitis and any sign of hypersensitivity.
Fibrates and niacin target triglycerides and bring their own risks
Fibrates mainly lower triglycerides. Combined with statins, especially gemfibrozil, they raise the risk of myopathy, so unexplained muscle pain, weakness or dark urine needs prompt reporting. Fibrates can also promote gallstones and need caution in renal impairment, so right upper abdominal pain and kidney results are part of the assessment.
Niacin commonly causes flushing, itching and warmth shortly after a dose. The prescriber may advise aspirin or an NSAID beforehand to reduce it, and the episodes usually pass within minutes. Niacin can raise blood glucose and uric acid and can injure the liver, so diabetes, gout and liver results deserve attention.
Bile acid sequestrants bind more than bile
Cholestyramine, colestipol and colesevelam bind bile acids in the gut, forcing the liver to use cholesterol to make more. They are not absorbed, but they cause constipation, bloating and abdominal discomfort, so fluid and fibre advice is part of teaching. They can raise triglycerides and are avoided when triglycerides are very high.
These resins bind many other medicines and fat-soluble vitamins. Separating other drugs from the resin by several hours is standard, and ezetimibe is taken at least two hours before or four hours after a sequestrant. When a patient on a resin has a poorly controlled condition, check whether doses are being taken together.
Hold and report triggers across the group
Report muscle pain or weakness, dark urine, yellowing skin or eyes, right upper abdominal pain or persistent nausea before the next dose of any of these drugs, particularly when two lipid agents are combined. These symptoms can reflect myopathy, liver injury or gallstones, and the prescriber decides whether to continue, stop or test.
For sequestrants, report severe constipation or abdominal distension, and check for missed vitamin or medication effects. For PCSK9 inhibitors, report rash, swelling or breathing difficulty after an injection. For niacin, report rising glucose readings or gout flares. Linking each symptom to its likely drug helps the prescriber adjust therapy safely.
Monitoring, teaching and an original scenario
A repeat lipid panel some weeks after starting or changing therapy shows whether treatment is working. Teach that these drugs support, rather than replace, diet, activity and smoking cessation. Ask patients to bring every medicine and supplement to appointments, since interactions and timing problems often surface only when the full list is reviewed.
In a hypothetical case, a patient taking a statin and newly prescribed gemfibrozil reports aching thighs and cola-coloured urine. Options are to suggest stretching, advise taking the doses further apart, or hold the next doses and notify the prescriber promptly. Holding and notifying is strongest, because these symptoms may indicate rhabdomyolysis, which needs creatine kinase and kidney assessment. Separating dose times helps with sequestrant binding but does nothing for muscle toxicity, and stretching treats the symptom as trivial. Matching the symptom to the drug combination is the skill being tested.
Sources and further reading
StatPearls: Lipid-Lowering Drug Therapy. Niacin flushing and pre-treatment, fibrate myopathy and gallstones, bile acid sequestrant effects and drug binding, PCSK9 injection reactions.
StatPearls: Ezetimibe. Ezetimibe mechanism, liver test monitoring, sequestrant timing and muscle symptom teaching.
StatPearls: PCSK9 Inhibitors. Subcutaneous administration, inclisiran schedule, adverse effects and LDL rechecks.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our cardiovascular practice questions are the closest set to what this page covers.
Common questions
How should ezetimibe be timed with cholestyramine?
Ezetimibe is taken at least two hours before or four hours after a bile acid sequestrant, because the resin can bind it and reduce absorption.
Is flushing after niacin an allergic reaction?
Usually not. Flushing is a common, short-lived effect. The prescriber may recommend aspirin or an NSAID beforehand. Wheeze, swelling or hives would need urgent assessment.
Which non-statin is given by injection?
PCSK9 inhibitors such as evolocumab and alirocumab are self-injected subcutaneously; inclisiran is also injected, at longer intervals, by a clinician.
More on cardiovascular
Guides on this